Nationwide Recall of Dexmedetomidine Injection Due to Contamination Concerns

Nationwide Recall of Dexmedetomidine HCl Injection

Par Health has announced a voluntary recall affecting two specific lots of its Dexmedetomidine HCl in 0.9% Sodium Chloride Injection, owing to concerns regarding contamination with particulate matter, identified as cellulose or stopper material. This has raised alarms within the medical community due to the potential health risks associated with using the affected product.

Details of the Recall

The recall includes Dexmedetomidine HCl formulated for intravenous infusion, which is generally prescribed for sedation in adult patients either during mechanical ventilation in intensive care units or before surgical procedures. The affected lots are labeled with Lot Numbers 87558 and 88802 and were distributed across the U.S. from May 13, 2025, to June 29, 2025. Both lots have expiration dates set for February and April 2027, respectively.

The presence of particulate matter in injectable medications significantly increases the risk of severe adverse effects, including pulmonary emboli, blood vessel occlusions that may lead to tissue death, and inflammation of venous walls, which can further trigger clotting complications. Par Health has reported no incidents of adverse events linked to this specific recall, a relief to both the company and healthcare providers who depend on this medication.

Impact on Healthcare

The decision to recall these lots reflects a serious commitment to patient safety. Hospitals, pharmacies, and healthcare providers in possession of the recalled products are urged to immediately cease distribution and use of the affected lots. Par Health is actively working with wholesale distributors and healthcare facilities to manage the return of these products through a coordinated plan involving Inmar, Inc.

Patients and healthcare professionals are advised to carefully monitor any alternative medications or dosages for those relying on Dexmedetomidine for sedation. Details for communicating any further distribution of the affected product to various healthcare accounts have been made available, ensuring proper tracking and mitigation efforts.

For direct inquiries regarding the recall, affected parties can contact Inmar, Inc. at 1-833-599-3197 during business hours. In addition, medical or technical inquiries related to the product can be channeled through Par Health’s dedicated hotline at 1-800-828-9393. The firm adheres closely to the reporting protocols established by the FDA for addressing any adverse reactions or product quality concerns.

Conclusion

In conclusion, the recall of the Dexmedetomidine HCl product lineup is a proactive measure to safeguard patient health. Par Health's responsiveness to this situation highlights its dedication to ensuring that the highest safety standards are met in health care settings. As investigations continue into how the particulate matter ended up in these lots, the priority remains on ensuring the well-being of patients across the nation. Health care professionals are urged to stay informed about the recall and ensure that their practices align with the latest FDA advisories to maintain the safety and efficacy of patient care.

For further information, individuals can also report adverse effects through the FDA's MedWatch Adverse Event Reporting program, ensuring transparency and accountability in the healthcare system.